Hidradenitis Suppurativa | Treatment Algorithms: Claims Data Analysis | US | 2023
Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disorder affecting hair follicles. It is characterized by inflamed and swollen lesions that are typically painful and filled with fluid or pus. Currently, AbbVie’s Humira (adalimumab) is the only FDA-approved therapy for HS. Humira is approved specifically for moderate to severe disease, and depending on their specific symptoms, patients may initially receive off-label treatment with other agents, such as antibiotics and immunosuppressants. Alternative biologics may also be used off-label for patients with more-severe disease and/or who do not respond to Humira (e.g., Janssen’s Remicade [infliximab]). This content will provide manufacturers of current treatments, as well as those developing novel HS agents, with insight into the use of various drugs to treat HS and the market trends in this disease space.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HS patients?
- How has Humira been integrated into the treatment algorithm, and what is its source of business?
- What percentage of HS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Amgen, Janssen, Novartis, Eli Lilly, Sobi, Bausch Health, UCB, Sun Pharmaceuticals
Key drugs: Humira, Remicade, infliximab biosimilars, Enbrel, Stelara, Simponi, clindamycin, doxycycline, acitretin, methotrexate, dapsone, cyclosporine, tacrolimus, Otezla, Cosentyx, Taltz, Tremfya, Skyrizi, Ilumya, Cimzia
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
